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Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at the 
time of publication and may evolve as the science develops. 
INTRODUCTION
A novel coronavirus disease (COVID-19), caused by 
SARS-CoV-2, has rapidly spread throughout many countries 
including the United States since its discovery in December 
2019.1 Many locations in the US are looking to rapidly expand 
their testing capabilities for this virus as they believe this 
could provide an important means to battle the COVID-19 
pandemic.2-6 However, the benefit of widespread testing 
depends on the accuracy of the test, and how the results of the 
test will affect treatment. For mild cases of COVID-19 (which 
are the primary target of the outpatient testing facilities), 
no specific medications are indicated, so in most cases, the 
results of the test would not change treatment. With regard 
to the accuracy of the test, the most commonly used test for 
detecting SARS-CoV-2 is a nasopharyngeal swab that uses 
a reverse transcriptase-polymerase chain reaction (RT-PCR) 
to identify viral RNA. Data from in vitro analyses suggest 
that the RT-PCR test is highly specific for SARS-CoV-2, as 
it is not positive when exposed to the nucleic acid of other 
common viruses.7 Similarly, the in vitro sensitivity of RT-
PCR tests is high, but in clinical settings the sensitivity of the 
nasopharyngeal RT-PCR swab tests for diagnosing COVID-19 
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is questionable. This article will review the clinical data 
regarding the accuracy of the COVID-19 RT-PCR test. 
SUMMARY OF THE LITERATURE REGARDING 
COVID-19 TESTING 
At this time, no peer-reviewed publications have reported 
a sensitivity and specificity of RT-PCR tests for COVID-19. 
One non-peer reviewed publication reports that, based on 
87 Chinese patients who were ultimately diagnosed with 
COVID-19, pharyngeal RT-PCR tests have a sensitivity and 
specificity of 78.2% and 98.8%, respectively.8 The sensitivity 
was 62.5% for “mild” cases.8 While no other publications 
currently provide estimates of the sensitivity and specificity, 
several peer-reviewed publications have provided evidence 
of a substantial false negative rate with RT-PCR swab tests as 
described below.
First, a study by Wang et al took various types of 
specimens from 205 patients with confirmed COVID-19 and 
tested them with RT-PCR. Of 398 pharyngeal swabs, they 
found only 126 (32%) were positive. They took just eight 
nasal swabs, and found five (63%) were positive.9 (As a side 
note, the US Centers for Disease Control and Prevention 
has reported that nasopharyngeal swabs seem to be more 
sensitive than oropharyngeal swabs, and thus recommends 
nasopharyngeal testing over oropharyngeal testing.10) Wang 
et al also analyzed specimens from bronchoalveolar lavage 
(BAL) fluid and sputum and found these were positive in 93% 
and 72% of cases, respectively.9 
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Along the same lines, Winichakoon et al published a letter 
to the editor in which they described a case of a COVID-19 
patient who had a nasopharygeal/oropharyngeal RT-PCR 
swab that was negative for COVID-19, but RT-PCR of BAL 
fluid was positive.11 Additionally, 19 cases of patients with 
suspected COVID-19 were reviewed in another small study. 
Oropharyngeal RT-PCR swab tests were performed in all 19 
patients, but were positive in just nine (47.4%).12
Next, in a case series described by Xie et al, five patients 
from the Hunan province of China had ground-glass opacities 
on chest computed tomography (CT) that were suggestive 
of COVID-19, but initial pharyngeal RT-PCR tests were 
negative. Repeat RT-PCR swabs ended up being positive.13 
Similarly, Fang et al analyzed 51 patients who were ultimately 
confirmed to have COVID-19 who had both a chest CT 
and RT-PCR testing by either throat swab (45 patients) or 
sputum (six patients) upon admission to the hospital. Of 
those 51 patients, the chest CTs had characteristic findings of 
COVID-19 in 50 (98%). Comparatively, the initial RT-PCR 
test was positive in 36 of 51 (71%).14 
Other studies have also demonstrated that initial RT-PCR 
tests may be negative and then become positive with repeated 
tests. For example, Wu et al studied the clinical course of 
80 patients from the Jiangsu Province who were ultimately 
diagnosed with COVID-19. Nine of those 80 patients (11.3%) 
had two negative RT-PCR nasal or oral swabs before their 
third swabs came back positive.15 Additionally, Young et al 
reported the results from daily nasopharyngeal RT-PCR testing 
that were taken from 18 patients from Singapore who were 
hospitalized for COVID-19. Interestingly, some patients had 
positive tests, and then negative tests, and then positive tests 
again, all within the same hospitalization.16 
DISCUSSION
The sensitivity and specificity of nasopharyngeal swabs 
using RT-PCR for the diagnosis of COVID-19 cannot be 
precisely determined with the published data to this point. 
However, the available in vitro data along with minimal 
clinical data suggest that the test has very high specificity. On 
the other hand, the sensitivity is moderate (perhaps between 
63-78%). Among the various ways of performing RT-PCR, 
pharyngeal swabs seem to have lowest sensitivity; nasal swabs 
may be a bit more sensitive than pharyngeal swabs. RT-PCR 
analysis of BAL fluid seems to be the most accurate means 
of virologic confirmation, but BAL fluid can only reasonably 
be collected on the sickest cohort of patients. For patients 
with moderate to severe COVID-19 symptoms, identifying 
characteristic findings on CT imaging of the chest may be 
more sensitive than RT-PCR testing. 
Given these findings, when a patient has a high pretest 
probability for COVID-19, a negative test does not rule out the 
disease. Consequently, policies that assume a high accuracy of 
RT-PCR testing are perilous. For example, employers should 
not use a negative test result to decide when someone should 
return to work. Meanwhile, the perceived need for increased 
testing propagated by the popular media17 may lead some 
patients to visit the ED solely for an unnecessary test, which 
could put those individuals at increased risk for COVID-19 if 
they do not already have it. As there is no treatment needed for 
mild cases of COVID-19, patients with mild symptoms need 
not go to the emergency department or get testing; instead, 
they should self-quarantine. 
Increased testing could be beneficial in areas of the world 
where there are very few cases of COVID-19. Aggressive 
early testing could allow for early identification of cases 
to allow for early targeted isolation and social distancing 
measures. However, in cities where COVID-19 is already 
widespread, the testing of large numbers of individuals with 
mild illness will have minimal effect on treatment but will 
require massive resources. There is epidemiological benefit to 
testing, but in cities already being devastated by COVID-19, 
the numbers of hospitalizations and mortalities associated with 
it can be used as indicators of disease impact. Reduced testing 
of patients with mild disease could save testing materials so 
that sicker patients and healthcare professionals will have 
access to testing. Additionally, a large amount of personal 
protective equipment could be saved by not attempting to test 
the many thousands and perhaps what will be millions of mild 
COVID-19 cases. 
CONCLUSION
While the exact sensitivity and specificity of RT-PCR tests 
for COVID-19 are not known, it appears that a positive test is 
highly suggestive of true COVID-19, but a negative test does 
not rule out the disease. Patients and providers in epidemic 
areas should assume they have the disease if they have the 
signs and symptoms of the disease even if their test was 
negative. The push for increased testing in areas that already 
have widespread COVID-19 may be overstated, as the benefits 
of large-scale use of a moderate sensitivity test are minimal.
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